Teva Bets on Open Innovation with 'Teva Rise' Platform

TEL AVIV, November 19, 2025 – Teva Pharmaceutical Industries Ltd. today announced the launch of ‘Teva Rise,’ a global open innovation platform designed to tap into external expertise and accelerate innovation across its core business areas. The platform invites startups and tech companies to collaborate on challenges spanning Artificial Intelligence (AI), Industry 4.0, smart manufacturing, digital health, and biotech – a move analysts say reflects a growing industry trend toward collaborative research and development.

A Strategic Pivot for a Generics Giant

Teva, traditionally known as a leading generics manufacturer, is undergoing a significant strategic evolution. 'Teva Rise' is central to this 'Pivot to Growth' strategy, signaling a commitment to expanding beyond generics and investing in innovative therapies and technologies. The company’s recent positive financial performance, with eleven consecutive quarters of growth reported in Q3 2025, demonstrates a stable financial foundation to support this substantial investment in innovation.

“The pharmaceutical landscape is changing rapidly,” says one industry analyst. “Companies can no longer rely solely on internal R&D. Open innovation allows them to access a wider pool of expertise and accelerate the development of new solutions.”

The launch comes at a time when the pharmaceutical industry is facing increasing pressure to reduce costs, improve efficiency, and bring new therapies to market faster. By leveraging external innovation, Teva aims to address these challenges and strengthen its competitive position.

The Rise of Collaborative R&D

Teva isn’t alone in embracing open innovation. Major pharmaceutical companies like Pfizer, Novartis, and Johnson & Johnson have established their own innovation hubs and venture capital arms. These initiatives reflect a growing recognition that collaboration is essential for driving breakthrough innovation.

However, Teva’s 'Teva Rise' differentiates itself by focusing on a broad range of disruptive technologies and explicitly inviting collaboration on specific challenges across the entire pharmaceutical value chain. Unlike some competitors that primarily focus on venture investments, Teva’s platform emphasizes co-creation and integration of external solutions into its global operations.

“The key is not just finding innovative technologies, but also integrating them seamlessly into existing processes and systems,” explains a technology consultant specializing in the pharmaceutical industry. “Teva’s platform appears to be designed with this integration in mind.”

Seven Challenges, Broad Impact

The 'Teva Rise' platform launched with seven initial challenges, covering areas critical to Teva's business: developing human-predictive platforms for testing biologics, leveraging AI for clinical trial optimization, improving manufacturing processes with Industry 4.0 technologies, enhancing supply chain resilience, utilizing digital health solutions for patient engagement, applying AI for commercial strategy, and exploring biotech innovations for novel therapies.

“These challenges are very practical and address significant pain points in the industry,” says one source familiar with the platform. “They’re not just theoretical exercises; they’re focused on solving real-world problems.”

The challenges also align with broader industry trends. The demand for more accurate preclinical models, the need to optimize clinical trials, the benefits of smart manufacturing, and the potential of digital health are all areas of increasing focus for pharmaceutical companies. By tackling these challenges, Teva aims to position itself at the forefront of innovation and drive meaningful improvements in patient care.

The company is specifically seeking solutions that can accelerate drug discovery, improve manufacturing efficiency, enhance supply chain resilience, and improve patient outcomes.